Ark Israel Inno Techno

Berenberg Downgrades Mobileye, Cuts Rating to Hold, Shares Drop 1.8% as Jefferies Issues Underperform

Radcom released FY2026 Q1 earnings on May 19 Pre-Market (EST), actual revenue USD 18.59 M (forecast USD 18.61 M), actual EPS USD 0.18

Radcom Q1 Earnings: Revenue Misses Expectations Slightly, New AI Engine Neura Unveiled as Stock Drops 4.29%

Alpha Tau Medical released FY2026 Q1 earnings on May 18 (EST), actual revenue USD 0 (forecast USD 66.33 K), actual EPS USD -0.26

JFrog CTO Yoav Landman Sells 75,000 Shares for $4.82 Million

JFrog Director Frederic Simon Sells 117,500 Shares for $7.48 Million

Tower Semicon released FY2026 Q1 earnings on May 13 During-Market (EST), actual revenue USD 413.63 M (forecast USD 410.98 M), actual EPS USD 0.57 (forecast USD 0.475)

Valens Semiconductor released FY2026 Q1 earnings on May 13 Pre-Market (EST), actual revenue USD 16.86 M (forecast USD 16.47 M), actual EPS USD -0.0789 (forecast USD -0.11)

SimilarWeb released FY2026 Q1 earnings on May 13 Pre-Market (EST), actual revenue USD 73.88 M (forecast USD 73.04 M), actual EPS USD -0.0728 (forecast USD -0.0466)

UroGen Pharma Reports 64.5% Durable Response Rate for ZUSDURI in Phase III Envision Trial

Tower Semiconductor Signs 1.3 Billion Dollar Silicon Photonics Contract

Radcom to release FY2026 Q1 earnings report on May 19, pre-market EST, with forecast revenue of USD 18.61 M

Alpha Tau Medical REGAIN Trial Shows Positive Results for Glioblastoma Treatment

Barclays analyst maintains buy rating on JFrog stock

JFrog released FY2026 Q1 earnings on May 8 After-Market (EST), actual revenue USD 153.98 M (forecast USD 147.49 M), actual EPS USD -0.0699 (forecast USD -0.1521)

S&P Maintains Positive Credit Outlook for Tower Semiconductor

Alpha Tau Medical Ltd. Completes Patient Recruitment for Alpha DaRT Radiotherapy Key Clinical Trial

JFrog Raises Fiscal Outlook and Announces $300M Stock Buyback, Shares Up Pre-Market

Taboola.com released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 466.4 M (forecast USD 453.25 M), actual EPS USD 0.2161 (forecast USD -0.0283)

Urogen Pharma released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 50.96 M (forecast USD 44.82 M), actual EPS USD -0.4699 (forecast USD -0.4814)

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

FROG

JFrog Ltd. (NASDAQ:FROG) reached a new 52-week high of $72.36, closing at $72.28 with significant trading volume. Analysts have mixed ratings, with 18 recommending 'Buy' and one 'Sell'. The company reported a Q1 EPS of $0.27, exceeding estimates, and a revenue increase of 25.8% year-over-year. JFrog's market cap is $8.82 billion, and it has set FY 2026 EPS guidance between 0.930-0.970. Recent insider sales were noted, and institutional investors have increased their stakes in the company.

Market Beat

JFrog

iShares Expanded Tech Software Sector ETF

SPDR S&P Software

ROYAL BANK OF CANADA

Goldman Sachs

GS Hldg R

JFrog (NASDAQ:FROG) Reaches New 52-Week High  - Still a Buy?

DRTS

Alpha Tau Medical Ltd. reported a Q1 2026 net loss of $22.9 million, up from $8.7 million a year prior. The company plans to complete patient recruitment for its IMPACT pancreatic cancer study by Q3 2026 and expects initial data by late 2026. The stock closed at $10.03, down 3.19%, but rose 3.09% in pre-market trading to $10.34.

nasdaq

Alpha Tau Medical

Nasdaq

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

Alpha Tau Q1 Net Loss Expands; Plans Enrollment Completion In IMPACT Study In Q3,2026; Stock Up

SMWB

Similarweb Ltd. (NYSE:SMWB) experienced a 54.8% decline in short interest in April, totaling 258,981 shares as of April 30th. The short-interest ratio is currently 0.5 days. The company reported Q1 2026 results that met EPS expectations and provided a revenue outlook of $307M-$315M for the year. Analysts have mixed opinions on the stock, with an average rating of 'Hold' and a consensus price target of $7.07.

SimilarWeb

Riskified

Similarweb Ltd. (NYSE:SMWB) Short Interest Down 54.8% in April

SOXX

SOXL

Valens Semiconductor (NYSE:VLN) reported Q1 earnings of ($0.05) EPS, beating estimates by $0.01. Revenue was $16.86 million, exceeding the $16.47 million forecast. The company has a negative return on equity of 27% and a net margin of 44.72%. Management projects Q2 revenue between $17.2 million and $17.6 million, with a full-year guidance of $75 million to $77 million. The CFO will leave on July 13. Shares rose to $3.40, with a market cap of $350.78 million. Insider trading activity includes a director selling shares, and institutional investors have increased their stakes.

Valens Semiconductor

VanEck Semiconductor ETF

iShares Semiconductor ETF

Direxion Semicon Bull 3X

Man Group PLC

VALENS SEMICONDUCTOR LTD C/WTS 30/09/2026 (TO PUR COM)

Valens Semiconductor (NYSE:VLN) Releases Earnings Results, Beats Estimates By $0.01 EPS

Valens (VLN) held its Q1 earnings call, revealing a cautiously optimistic outlook. Revenue reached $16.9 million, slightly above guidance but down 12.9% sequentially. Gross margins exceeded expectations at 62.2%. The automotive segment grew to $5.9 million, while Cross-Industry Business revenue fell 20.9%. Adjusted EBITDA loss narrowed to $5.5 million, with cash reserves at $86.1 million. However, management noted risks from customer concentration in automotive and a CFO transition, which may impact execution. Full-year revenue guidance remains unchanged at $75–$77 million, relying on a second-half ramp for growth.

Tip Ranks

Mercedes-Benz Group AG

Valens’ Earnings Call Balances Momentum With Risk

ARKG

Dror Ortho-Design, Inc. reported a net loss of $(638,666) for Q1 2026, with diluted EPS of $(0.00). The company remains in the development stage with no material revenue. R&D spending decreased by 51% year-over-year. The company is preparing a new 510(k) submission for FDA clearance and aims to disrupt the aligner market with a smart aligner platform. Operations depend on raising additional capital for regulatory work and development. Following a share exchange in 2023, the company integrated a new management team for commercialization efforts.

TradingView

Ark Genomic Revolution ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

VG Health

iShares Global Healthcare

iShares US Pharma

Direxion S&P Biotech Bear 3X

Dror Ortho-Design, Inc. 1Q 2026: Net income $(638,666), EPS $(0.00) — 10-Q Summary

Valens Semiconductor (NYSE:VLN) reported Q1 2026 revenues of $16.9 million, exceeding guidance. GAAP gross margin was 62.2%, while adjusted EBITDA showed a loss of $5.5 million, smaller than expected. The company noted strong adoption of its VS3000 and VS6320 chips, with strategic partnerships enhancing market position. Guidance for Q2 2026 projects revenues between $17.2 million and $17.6 million, maintaining a full-year outlook of $75-77 million. CFO Guy Nathanson announced his departure, with a search for a replacement underway.

fidelity

Full Transcript: Valens Semiconductor Q1 2026 Earnings Call

Similarweb shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

benzinga_article

Similarweb (NYSE:SMWB) reported Q1 2026 earnings with a 10% year-over-year revenue growth to $73.9 million, meeting guidance. The CEO announced plans to step down by mid-2027, coinciding with the company's 20-year milestone. The company raised its 2026 revenue guidance to $307-$315 million, driven by AI-related revenues and strong customer retention (98% NRR). New product launches are expected to enhance growth. Similarweb maintained positive normalized free cash flow for the tenth consecutive quarter, with management optimistic about the second half of 2026 due to a strong sales pipeline.

Similarweb Reports Q1 2026 Results: Full Earnings Call Transcript

Valens Semiconductor Ltd. (NYSE: VLN) reported 1Q26 revenue of $16.9M, down from $19.4M in 4Q25 but slightly up from $16.8M in 1Q25. The GAAP gross margin was 62.2%, exceeding guidance. Adjusted EBITDA loss was $(5.5) M, better than expected. Management reiterated FY26 revenue guidance of $75.0M-$77.0M, anticipating growth in the second half of the year driven by CIB growth and automotive stability. Supply-chain conditions are being monitored, but no risks to full-year targets were noted. Automotive revenue reached $5.9M, with potential growth in adjacent markets.

StockTitan

Stonegate Capital Partners Updates Coverage on Valens Semiconductor Ltd. (VLN) 1Q26 | VLN Stock News

Ark Israel Inno Techno(IZRL.US)

JFrog (NASDAQ:FROG) Reaches New 52-Week High - Still a Buy?